Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for Age-related Macular Degeneration
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced a collaboration with the Singapore Eye Research Institute (SERI) to expand knowledge and identify new targets associated with AMD. Under the terms of the agreement, SERI and Gemini will explore the link between genetic and potential biomarkers in patients diagnosed with pol